PMID- 12869823
OWN - NLM
STAT- MEDLINE
DCOM- 20040506
LR  - 20161124
IS  - 0143-3636 (Print)
IS  - 0143-3636 (Linking)
VI  - 24
IP  - 8
DP  - 2003 Aug
TI  - Angiotensin-converting enzyme inhibition improves cardiac fatty acid metabolism 
      in patients with congestive heart failure.
PG  - 901-6
AB  - This study aimed to examine whether angiotensin-converting enzyme (ACE) 
      inhibition improved cardiac fatty acid metabolism in patients with congestive 
      heart failure (CHF). Myocardial 123I-beta-methyl-iodophenylpentadecanoic acid 
      (123I-BMIPP) imaging was performed in 25 patients with CHF and in 10 control 
      subjects. Myocardial 123I-BMIPP images were obtained 30 min and 4 h after tracer 
      injection. The heart-to-mediastinum (H/M) ratio of 123I-BMIPP uptake and the 
      washout rate of 123I-BMIPP from the myocardium were calculated. Patients were 
      given enalapril for 6 months, and 123I-BMIPP imaging was repeated. H/M ratios on 
      early and delayed images were lower in CHF patients than in normal controls 
      (P<0.01). The washout rate of 123I-BMIPP from the myocardium was faster in CHF 
      patients than in controls (P<0.01). As the severity of the New York Heart 
      Association (NYHA) functional class increased, the H/M ratio decreased and the 
      washout rate increased. The washout rate of 123I-BMIPP was inversely correlated 
      with left ventricular fractional shortening (R=-0.62, P<0.01). ACE inhibition 
      with enalapril increased the H/M ratio on delayed images (P<0.05) and reduced the 
      washout rate of 123I-BMIPP (P<0.05) in CHF patients. These data suggest that: (1) 
      angiotensin II-mediated intracellular signalling activation may be a possible 
      mechanism for the decreased myocardial uptake and enhanced washout of 123I-BMIPP 
      in heart failure patients; and (2) the improvement in fatty acid metabolism by 
      ACE inhibition may represent a new mechanism for the beneficial effect of this 
      therapy in heart failure.
FAU - Yamauchi, S
AU  - Yamauchi S
AD  - First Department of Internal Medicine, Yamagata University School of Medicine, 
      Yamagata, Japan. takeishi@med.id.yamagata-u.ac.jp
FAU - Takeishi, Y
AU  - Takeishi Y
FAU - Minamihaba, O
AU  - Minamihaba O
FAU - Arimoto, T
AU  - Arimoto T
FAU - Hirono, O
AU  - Hirono O
FAU - Takahashi, H
AU  - Takahashi H
FAU - Miyamoto, T
AU  - Miyamoto T
FAU - Nitobe, J
AU  - Nitobe J
FAU - Nozaki, N
AU  - Nozaki N
FAU - Tachibana, H
AU  - Tachibana H
FAU - Watanabe, T
AU  - Watanabe T
FAU - Fukui, A
AU  - Fukui A
FAU - Kubota, I
AU  - Kubota I
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nucl Med Commun
JT  - Nuclear medicine communications
JID - 8201017
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Fatty Acids)
RN  - 0 (Iodobenzenes)
RN  - 0 (Radiopharmaceuticals)
RN  - 0J7USQ749M (iodofiltic acid)
RN  - 69PN84IO1A (Enalapril)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*administration & dosage
MH  - Enalapril/*administration & dosage
MH  - Fatty Acids/*metabolism/pharmacokinetics
MH  - Female
MH  - Heart/*diagnostic imaging/*drug effects
MH  - Heart Failure/drug therapy/*metabolism
MH  - Humans
MH  - *Iodobenzenes/pharmacokinetics
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*metabolism
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals/pharmacokinetics
EDAT- 2003/07/19 05:00
MHDA- 2004/05/07 05:00
CRDT- 2003/07/19 05:00
PHST- 2003/07/19 05:00 [pubmed]
PHST- 2004/05/07 05:00 [medline]
PHST- 2003/07/19 05:00 [entrez]
AID - 10.1097/01.mnm.0000084579.51410.69 [doi]
PST - ppublish
SO  - Nucl Med Commun. 2003 Aug;24(8):901-6. doi: 10.1097/01.mnm.0000084579.51410.69.